257 related articles for article (PubMed ID: 15764267)
21. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
Kurokawa S; Morita T; Muraishi O; Tokue A
Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
[TBL] [Abstract][Full Text] [Related]
22. [Significance of urinary nuclear matrix protein 22 in diagnosis of transitional cell carcinoma of urinary tract].
Shao Y; Zhuang J; Xu SX; Liu DY
Ai Zheng; 2002 Sep; 21(9):1005-7. PubMed ID: 12508552
[TBL] [Abstract][Full Text] [Related]
23. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay.
Sherief MH; Low SH; Miura M; Kudo N; Novick AC; Weimbs T
J Urol; 2003 Apr; 169(4):1530-4. PubMed ID: 12629409
[TBL] [Abstract][Full Text] [Related]
25. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
Lotan Y; Capitanio U; Shariat SF; Hutterer GC; Karakiewicz PI
BJU Int; 2009 May; 103(10):1368-74. PubMed ID: 19338566
[TBL] [Abstract][Full Text] [Related]
26. Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy.
Dong ZL; Lu ZP; Wang HZ; Zhang LY; Wang ZP; Zhang YF; Ma BL
Urol Int; 2011; 87(4):445-9. PubMed ID: 22056470
[TBL] [Abstract][Full Text] [Related]
27. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
28. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22.
Raina R; Pahlajani G; Ponsky LE; Agarwal A; Zippe CD
BJU Int; 2008 Aug; 102(3):297-300. PubMed ID: 18702780
[TBL] [Abstract][Full Text] [Related]
29. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
[TBL] [Abstract][Full Text] [Related]
30. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
[TBL] [Abstract][Full Text] [Related]
31. [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
Yokoyama T; Sekigawa R; Hayashi T; Horita S; Kanamuro T; Nonami Y; Sawada T; Nishikawa T; Kobayashi M; Yamaguchi Y; Ishida H; Goya N; Nakazawa H; Toma H
Rinsho Byori; 2004 Mar; 52(3):199-203. PubMed ID: 15137316
[TBL] [Abstract][Full Text] [Related]
32. Identification of nuclear matrix protein alterations associated with renal cell carcinoma.
Konety BR; Nangia AK; Nguyen TS; Veitmeier BN; Dhir R; Acierno JS; Becich MJ; Hrebinko RL; Getzenberg RH
J Urol; 1998 Apr; 159(4):1359-63. PubMed ID: 9507884
[TBL] [Abstract][Full Text] [Related]
33. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
[TBL] [Abstract][Full Text] [Related]
34. [Study on urinary levels of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha in patients with renal cell carcinoma].
Shi B; Nakazawa H; Ryoji O; Goya N; Ito F; Koga S; Okuda H; Kobayashi H; Toma H
Hinyokika Kiyo; 1998 Mar; 44(3):143-7. PubMed ID: 9589873
[TBL] [Abstract][Full Text] [Related]
35. Clinical study of urine NMP 22 (nuclear matrix protein 22) as a tumor marker in urinary epithelial cancer.
Takeuchi Y; Sawada Y; Yabuki D; Masuda E; Satou D; Kuroda K; Tajima M; Sawamura Y; Matsushima M
Aktuelle Urol; 2003 Jul; 34(4):265-6. PubMed ID: 14566681
[TBL] [Abstract][Full Text] [Related]
36. Value of urinary NMP-22 in patients with renal cell carcinoma.
Ozer G; Altinel M; Kocak B; Yazicioglu A; Gonenc F
Urology; 2002 Oct; 60(4):593-7. PubMed ID: 12385914
[TBL] [Abstract][Full Text] [Related]
37. Detection, staging and clinical implications of renal cell carcinoma.
Ghalayini IF; Bani-Hani IH
Saudi Med J; 2003 Jan; 24(1):79-83. PubMed ID: 12590282
[TBL] [Abstract][Full Text] [Related]
38. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis.
Mizutani Y; Nakanishi H; Li YN; Matsubara H; Yamamoto K; Sato N; Shiraishi T; Nakamura T; Mikami K; Okihara K; Takaha N; Ukimura O; Kawauchi A; Nonomura N; Bonavida B; Miki T
Int J Oncol; 2007 Apr; 30(4):919-25. PubMed ID: 17332931
[TBL] [Abstract][Full Text] [Related]
40. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]